Print

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors

Study Contact Information:

Pam Mangat by email at tapur@asco.org or at the study website www.tapur.org.

About the Study

The TAPUR Study is looking at the safety and efficacy of FDA-approved, targeted drugs to treat advanced cancers with certain tumor biomarkers. If interested, talk to your doctor about biomarker testing and visit www.tapur.org to find a participating center near you. 

What the Study Involves

The TAPUR Study is looking at many different cancer types, biomarkers, and drugs all in the same clinical trial. The study has broad eligibility, collects the minimum necessary data, and allows for flexibility in visits, treatment decisions, and care decisions to better benefit the participants. Each cancer type and treatment type follows different treatment timelines, so speak with the study contact if you have questions about what would be required of you if you are eligible and decide to join the study.

More about the Study

The TAPUR Study is a phase II, nonrandomized clinical trial. Phase II means that the study looks at efficacy and side effects of the anticancer study treatments. Nonrandomized means that participants are not randomly divided into treatment groups.

Lead Researchers/Study PIs and Affiliation

Richard Schilsky, MD, FACP, FSCT, FASCO TAPUR@asco.org

This Study is Open To:

To qualify for this study, you must have the following:

  1. Advanced cancer including: solid tumors (ex.: carcinomas, sarcomas), with a biomarker that can be targeted with a study drug. Your oncologist can help determine if this applies to you. You can view the list of biomarkers and cancer types here. 
  2. You are no longer benefitting from standard treatment or there is no standard treatment option/s available.
  3. You are healthy enough to participate.
  4. You are at least 12 years of age or older.*
  5. You are not currently pregnant and do not plan to become pregnant soon.
  6. The cancer is no longer responding to standard anti-cancer treatment or no standard treatment is available.
  7. You have had a genomic or molecular test performed on your tumor.
  8. You are out of bed and active at least half of each day.

* Some restrictions apply. Not all TAPUR Study therapies are available for participants under 18 years of age. Contact a participating TAPUR Study clinical site or the TAPUR Study team using the “Contact Us” form below to learn about the eligibility age for a specific study drug.

The dose, frequency, and duration of treatment will vary depending on the drug that the participant takes. Any additional biopsies, appointments, labs, etc. that are not required for screening will also vary depending on the drug that is being taken. Each drug has its own eligibility criteria.

This Study is Not Open To:

  1. You do not have an advanced cancer.
  2. You are on a current treatment that is beneficial to you.
  3. You are pregnant or plan to become pregnant soon.
  4. Your cancer is currently responding to standard anti-cancer treatment or there is standard treatment available to you. 
  5. You have not had a genomic or molecular test performed on your tumor.
  6. You are bed-ridden or not active at least half of each day. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.